The objective of this proposal is to advance medication development for alcoholism by
conducting a safety and initial efficacy study of ibudilast, a neuroimmune modulator and
phosphodiesterase inhibitor, for alcohol use disorders.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, Los Angeles
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)